JUNS

Jupiter Neurosciences

0.3800 USD
-0.0183
4.59%
At close Updated Apr 16, 10:35 AM EDT
1 day
-4.59%
5 days
-3.72%
1 month
-10.08%
3 months
-55.75%
6 months
-76.69%
Year to date
-62.38%
1 year
-46.23%
5 years
-93.08%
10 years
-93.08%
 

About: Jupiter Neurosciences Inc is a clinical-stage research and development company focused on developing treatments for neuroinflammation through the resveratrol platform. Its platform product, JOTROL, is an enhanced oral formulation of resveratrol, which has many potential indications. In the larger disease areas, which are targeting Parkinson's Disease. The group is presently in the process of conducting a Phase IIa clinical trial in Parkinson's Disease. The company operates through two reportable segments: premium nutritional supplements and pharmaceutical operations focused on drug candidates for CNS and rare orphan diseases. It generates the majority of its revenue from Premium Nutritional Supplements, which includes commercialization and sales of the Company's Nugevia product line.

Employees: 5

0
Funds holding %
of 8,116 funds
Analysts bullish %
0
Positive news %
Price charts implemented using Lightweight Charts™